Immunization in Children: Principles and Individual Vaccines
This is an exam-oriented pediatric note, aligned mainly with the
Indian National Immunization Schedule (NIS/UIP). The current NIS includes BCG, hepatitis B, OPV, pentavalent, fractional IPV, rotavirus vaccine, PCV, MR, JE in endemic areas, DPT boosters, and Td. Check the child’s immunization card and local program guidance because schedules and products may change. The
current Indian NIS chart is the practical reference.
1. Basic principles of immunization
Definition
Immunization is the process of making a person immune or resistant to an infectious disease, usually by vaccination.
A vaccine is an immunobiological preparation that stimulates specific protective immune responses, including antibodies, cellular immunity, and immunological memory. Vaccines may contain live attenuated organisms, killed organisms, toxoids, purified antigens, recombinant proteins, polysaccharides, or conjugated polysaccharides.
- Park’s Textbook of Preventive and Social Medicine, chapter on Vaccines.
2. Types of immunization
A. Active immunization
Active immunization means administration of an antigen to induce the person’s own immune response.
Characteristics
- Protection develops after a lag period, usually days to weeks.
- Produces immunological memory.
- Usually long-lasting.
- Booster doses may be needed.
- Given by vaccines or following natural infection.
Examples
- BCG
- Hepatitis B vaccine
- DPT/pentavalent vaccine
- MR/MMR
- IPV
- PCV
- HPV vaccine
B. Passive immunization
Passive immunization means transfer of preformed antibodies to a susceptible person.
Characteristics
- Protection is immediate.
- Protection is temporary because no immune memory develops.
- Used for post-exposure prophylaxis, toxin neutralization, or in immunodeficiency.
Preparations
- Human normal immunoglobulin
- Specific/hyperimmune immunoglobulin
- Hepatitis B immunoglobulin (HBIG)
- Rabies immunoglobulin (RIG)
- Tetanus immunoglobulin (TIG)
- Varicella-zoster immunoglobulin
- Antisera/antitoxins
- Diphtheria antitoxin
- Botulinum antitoxin
- Snake antivenom
- Maternal antibody transfer
- IgG through placenta
- Secretory IgA in breast milk
C. Combined active and passive immunization
Both are used when immediate protection and long-term immunity are required.
Examples
- Rabies exposure: rabies vaccine + RIG for category III exposure
- Tetanus-prone wound in inadequately immunized child: tetanus vaccine-containing preparation + TIG when indicated
- Infant born to an HBsAg-positive mother: hepatitis B vaccine + HBIG
Give vaccine and immunoglobulin at different anatomical sites, using separate syringes.
3. Classification of vaccines
| Type | Principle | Examples | Key point |
|---|
| Live attenuated | Weak but living organism replicates to a limited extent | BCG, OPV, rotavirus, measles, rubella, mumps, varicella, live JE | Strong, durable immunity; generally avoid in severe immunodeficiency and pregnancy |
| Inactivated/killed | Organism has been killed and cannot replicate | IPV, inactivated influenza, rabies, hepatitis A | Safer in immunodeficiency; usually requires multiple doses/boosters |
| Toxoid | Inactivated bacterial toxin | Tetanus toxoid, diphtheria toxoid | Protects against toxin-mediated disease; boosters required |
| Subunit/recombinant | Purified antigen/protein | Hepatitis B, HPV, acellular pertussis | Cannot cause the disease |
| Polysaccharide | Capsular polysaccharide antigen | PPSV23, older typhoid polysaccharide vaccine | Weak response in children below 2 years; poor memory |
| Conjugate | Polysaccharide linked to protein carrier | Hib, PCV, typhoid conjugate vaccine, meningococcal conjugate vaccine | Effective in infants; produces memory and booster response |
| Viral vector/mRNA | Genetic platform produces antigen in host cells | Some COVID-19 vaccines | Product and national recommendations vary |
Live vaccines generally give more durable immune responses because they mimic natural infection, but they require appropriate storage and have more restrictions in immunocompromised children. Inactivated vaccines cannot replicate and commonly need a primary series plus boosters.
- The Harriet Lane Handbook, “Immunoprophylaxis.”
- Park’s Textbook of Preventive and Social Medicine, chapter on Vaccines.
4. Herd immunity
Herd immunity is indirect protection of susceptible people when a sufficiently large proportion of the community is immune, reducing circulation and transmission of an organism.
Importance
- Protects infants too young to receive vaccines.
- Protects people with severe immunodeficiency who cannot receive live vaccines.
- Protects those in whom vaccination did not produce adequate immunity.
- Helps eliminate or eradicate diseases.
Factors affecting herd immunity
- Vaccine effectiveness
- Vaccine coverage
- Infectiousness of disease, expressed as the basic reproduction number, R₀
- Duration of immunity
- Population movement and clustering of unvaccinated individuals
Diseases with very high transmissibility, such as measles, require very high coverage, generally around 95%, to prevent outbreaks.
Herd immunity is not expected with tetanus, because tetanus is acquired from environmental spores and is not transmitted person-to-person.
5. General rules of vaccination
Simultaneous administration
- Multiple vaccines due at one visit should be given on the same day.
- Use separate syringes and separate sites.
- Do not mix vaccines in the same syringe unless supplied as a licensed combination product.
- This improves completion of the schedule and does not overload the immune system.
Spacing live vaccines
- Two injectable/nasal live vaccines should be given:
- on the same day, or
- separated by at least 4 weeks if not given together.
Interrupted schedules
- Never restart a vaccine series because of delay.
- Give the missed dose as soon as possible, observing the required minimum interval.
Mild illness is not a contraindication
Vaccination can usually be given in:
- Mild fever
- Common cold/cough
- Diarrhea without severe dehydration
- Malnutrition
- Breastfeeding
- Stable neurological disease
- Treatment with antibiotics
- Prematurity
6. Individual vaccines
A. BCG vaccine
| Item | Details |
|---|
| Full form | Bacillus Calmette-Guérin |
| Type | Live attenuated Mycobacterium bovis |
| Protects mainly against | Severe childhood tuberculosis, especially TB meningitis and miliary TB |
| UIP age | At birth or as early as possible until 1 year of age |
| Dose | 0.05 mL in infants younger than 1 year; 0.1 mL at 1 year or older |
| Route | Intradermal |
| Site | Left upper arm, insertion of deltoid |
| Scar | Usually develops in 6-12 weeks; its absence alone does not routinely indicate revaccination |
Adverse effects
- Local papule, ulcer, and scar are expected.
- Regional axillary lymphadenitis may occur.
- Rare: suppurative lymphadenitis, osteitis, disseminated BCG infection.
Contraindications
- Severe primary immunodeficiency
- Severe cellular immunodeficiency
- Child on significant immunosuppressive therapy
- Symptomatic HIV infection or known severe immunosuppression, according to national guidance
B. Hepatitis B vaccine
| Item | Details |
|---|
| Type | Recombinant subunit vaccine containing hepatitis B surface antigen |
| Disease prevented | Hepatitis B, chronic hepatitis, cirrhosis, hepatocellular carcinoma |
| UIP schedule | Birth dose, then at 6, 10, and 14 weeks through pentavalent vaccine |
| Birth dose timing | Preferably within 24 hours of birth |
| Dose | Usually 0.5 mL pediatric formulation |
| Route | Intramuscular |
| Site | Anterolateral thigh in infants; deltoid in older children |
Important points
- The birth dose is particularly important for prevention of mother-to-child transmission.
- Preterm and low-birth-weight babies should receive the birth dose according to national policy.
- If mother is HBsAg-positive, give hepatitis B vaccine plus HBIG as soon as possible, ideally within 12 hours, at different sites.
Adverse effects
- Mild pain, redness, fever
- Anaphylaxis is extremely rare.
C. Poliovirus vaccines
1. Oral polio vaccine (OPV)
| Item | Details |
|---|
| Type | Live attenuated oral vaccine |
| UIP schedule | OPV-0 at birth; OPV-1, 2, 3 at 6, 10, 14 weeks; booster at 16-23 months |
| Dose | 2 drops |
| Route | Oral |
| Purpose | Produces intestinal mucosal immunity and helps reduce community transmission |
Important: OPV is a live vaccine. Vaccine-associated paralytic poliomyelitis is very rare, but this is why IPV has an important role in polio-endgame strategies.
2. Inactivated polio vaccine (IPV/fIPV)
| Item | Details |
|---|
| Type | Inactivated/killed poliovirus vaccine |
| UIP schedule | Fractional IPV at 6 weeks, 14 weeks, and 9-11 months |
| Dose | fIPV is 0.1 mL |
| Route | Intradermal |
| Usual site | Right upper arm, according to program practice |
| Advantage | Cannot cause vaccine-associated paralytic polio |
IPV is safe in immunodeficiency, whereas OPV is generally avoided in children with significant immunodeficiency and in certain high-risk household situations.
D. DPT-containing vaccines and pentavalent vaccine
Components
- D: Diphtheria toxoid
- P: Pertussis vaccine, whole-cell or acellular
- T: Tetanus toxoid
The pentavalent vaccine contains:
| Item | Details |
|---|
| UIP primary series | 6, 10, and 14 weeks |
| Dose | 0.5 mL |
| Route | Intramuscular |
| Site | Anterolateral mid-thigh |
| UIP boosters | DPT booster at 16-23 months and 5-6 years; Td at 10 and 16 years |
Diseases prevented
- Diphtheria
- Pertussis
- Tetanus
- Hepatitis B
- Invasive Hib disease
Expected adverse effects
- Pain, redness, swelling
- Fever, irritability
- Persistent crying may occur, especially with whole-cell pertussis vaccine.
Important precautions
A previous severe allergic reaction to a vaccine component is a contraindication to further doses of that product. Encephalopathy occurring within 7 days after a pertussis-containing vaccine, without another identifiable cause, is a contraindication to further pertussis-containing doses.
E. Haemophilus influenzae type b vaccine (Hib)
| Item | Details |
|---|
| Type | Conjugate vaccine |
| Given as | Component of pentavalent vaccine under UIP |
| UIP schedule | 6, 10, and 14 weeks |
| Disease prevented | Hib meningitis, pneumonia, epiglottitis, sepsis, and other invasive Hib disease |
| Dose/route | Usually 0.5 mL IM as part of combination vaccine |
Hib vaccine does not protect against influenza virus. “Hib” refers to Haemophilus influenzae type b, a bacterium.
F. Rotavirus vaccine (RVV)
| Item | Details |
|---|
| Type | Live attenuated oral vaccine |
| UIP schedule | 6, 10, 14 weeks |
| Route | Oral |
| Disease prevented | Severe rotavirus gastroenteritis and hospitalization due to diarrhea |
| Number of doses | Depends on the product and national program; UIP uses 3 doses |
Key points
- Give orally. If the child spits out or regurgitates the dose, do not repeat it.
- Do not delay unnecessarily because rotavirus products have upper age limits.
- Contraindications include severe combined immunodeficiency and past intussusception.
- A small increased risk of intussusception has been reported after some rotavirus vaccines, but the benefits in preventing severe diarrheal disease are far greater.
G. Pneumococcal conjugate vaccine (PCV)
| Item | Details |
|---|
| Type | Conjugate vaccine |
| UIP schedule | PCV-1 at 6 weeks, PCV-2 at 14 weeks, booster at 9-11 months |
| Dose | 0.5 mL |
| Route | Intramuscular |
| Site | Anterolateral thigh |
| Disease prevented | Invasive pneumococcal disease, meningitis, bacteremia, pneumonia, and some otitis media |
High-risk children
Children with asplenia, cochlear implant, CSF leak, chronic cardiac/pulmonary disease, chronic kidney disease, diabetes, immunodeficiency, HIV, malignancy, or transplant may need additional pneumococcal vaccination, including PPSV23, based on specialist advice.
H. Measles-rubella vaccine (MR)
| Item | Details |
|---|
| Type | Live attenuated vaccine |
| UIP schedule | MR-1 at 9-11 months; MR-2 at 16-23 months |
| Dose | 0.5 mL |
| Route | Subcutaneous |
| Site | Right upper arm |
| Diseases prevented | Measles and rubella |
Importance
- Measles can cause pneumonia, diarrhea, encephalitis, malnutrition, blindness, and death.
- Rubella infection during pregnancy can lead to congenital rubella syndrome. Childhood vaccination helps prevent this.
Adverse effects
- Fever, mild rash, transient lymphadenopathy
- Febrile seizures may occur rarely.
- Thrombocytopenia is rare.
Contraindications
- Pregnancy
- Severe immunodeficiency
- Previous anaphylaxis to a vaccine component
- Defer after some immunoglobulin or blood-product exposures, because passively acquired antibody can reduce response.
I. MMR vaccine
| Item | Details |
|---|
| Components | Measles, mumps, rubella |
| Type | Live attenuated |
| Use in India | Commonly recommended in private/IAP practice; UIP provides MR rather than MMR |
| Dose | 0.5 mL SC |
| Site | Upper arm |
MMR adds protection against mumps, including mumps meningitis, orchitis, and hearing loss.
The exact MMR schedule should follow the current pediatrician/IAP recommendation and vaccine product instructions.
J. Japanese encephalitis vaccine
| Item | Details |
|---|
| Indication in UIP | Only in JE-endemic districts/areas |
| UIP schedule | JE-1 at 9-11 months and JE-2 at 16-23 months |
| Type | May be live attenuated or inactivated, depending on program/product |
| Route/dose | Product-specific |
JE is a mosquito-borne viral encephalitis that can cause severe neurological illness, disability, and death. It is not a universal vaccine in all Indian districts under UIP.
K. DPT booster and Td vaccine
DPT booster
| Age | Vaccine |
|---|
| 16-23 months | DPT booster-1 + OPV booster |
| 5-6 years | DPT booster-2 |
Td vaccine
| Age | Vaccine |
|---|
| 10 years | Td |
| 16 years | Td |
Td contains tetanus toxoid and reduced-dose diphtheria toxoid. It maintains protection against tetanus and diphtheria through adolescence.
7. Additional commonly recommended vaccines
These may not all be supplied through UIP everywhere. Their use depends on IAP recommendations, risk, travel, local epidemiology, product availability, and family preference.
A. Hepatitis A vaccine
| Item | Details |
|---|
| Type | Inactivated vaccine or live attenuated vaccine, depending on product |
| Usual age | From 12 months for inactivated vaccine; live product according to label |
| Route | IM for inactivated vaccine; product-specific for live vaccine |
| Protection | Hepatitis A and its complications |
Inactivated hepatitis A vaccine usually requires 2 doses. Follow the particular product schedule.
B. Typhoid conjugate vaccine (TCV)
| Item | Details |
|---|
| Type | Vi polysaccharide conjugated to carrier protein |
| Age | Can generally be given from 6 months, depending on product |
| Dose | Usually 0.5 mL |
| Route | IM |
| Protection | Typhoid fever due to Salmonella Typhi |
TCV is preferred over plain polysaccharide vaccine in young children because it generates T-cell-dependent immunity and immunological memory.
C. Influenza vaccine
| Item | Details |
|---|
| Type | Usually inactivated influenza vaccine for children |
| Age | From 6 months |
| Schedule | Annually |
| First season in child below 9 years | Two doses, at least 4 weeks apart, if not previously adequately vaccinated |
| Dose/route | Product- and age-specific; usually IM |
Annual vaccination is especially important in children with asthma, chronic lung/heart/kidney disease, diabetes, neurological disorders, immunodeficiency, obesity, and those receiving long-term aspirin therapy.
D. Varicella vaccine
| Item | Details |
|---|
| Type | Live attenuated |
| Protection | Chickenpox and its complications |
| Schedule | Usually 2 doses, following current pediatric recommendation |
| Route | SC |
Avoid in pregnancy and severe immunodeficiency.
E. Human papillomavirus vaccine (HPV)
| Item | Details |
|---|
| Type | Recombinant virus-like particle vaccine |
| Protection | HPV-related cervical, anal, genital, and some oropharyngeal cancers; genital warts depending on product |
| Best age | Before exposure to HPV, commonly 9-14 years |
| Route | IM, deltoid |
| Schedule | Product- and age-specific; usually 1 or 2 doses in younger adolescents, with 3 doses for older or immunocompromised recipients |
HPV vaccine is prophylactic. It does not treat established HPV infection.
F. Meningococcal vaccine
| Vaccine types | MenACWY conjugate; MenB in selected settings |
|---|
| Indications | High-risk children, asplenia, complement deficiency, travelers to epidemic areas, outbreak control, certain hostels/institutions |
| Route | IM |
| Schedule | Depends on age, risk, and product |
G. Rabies vaccine
Rabies vaccine is not a routine childhood vaccine in India. It is used after exposure and sometimes as pre-exposure prophylaxis in high-risk persons.
After animal bite/exposure
- Immediate and thorough wound washing with soap and running water for at least 15 minutes.
- Prompt medical assessment.
- Rabies vaccine for category II and III exposures.
- Rabies immunoglobulin for category III exposure, infiltrated into/around wounds whenever anatomically feasible.
Rabies is almost universally fatal after symptoms begin, but it is preventable with correct post-exposure prophylaxis.
8. True contraindications versus false contraindications
Important true contraindications
| Situation | Vaccine concern |
|---|
| Anaphylaxis after a previous dose or known severe allergy to component | Do not give same vaccine/component without expert assessment |
| Severe immunodeficiency | Avoid most live vaccines |
| Pregnancy | Avoid live vaccines |
| Encephalopathy within 7 days of pertussis vaccine, with no alternative cause | Do not give further pertussis-containing vaccine |
| SCID or previous intussusception | Rotavirus vaccine contraindicated |
Conditions that are usually not contraindications
- Mild fever or common cold
- Mild diarrhea
- Antibiotic use
- Breastfeeding
- Prematurity
- Low birth weight
- Malnutrition
- Family history of seizures
- Stable neurological disorder
- Controlled asthma or allergy
- Non-anaphylactic egg allergy for most routinely used vaccines
9. Key counseling points for parents
- Vaccines are given according to age because young children are at greatest risk of severe infection.
- Mild fever, pain, irritability, and swelling after vaccination are common and usually settle within 1-2 days.
- Bring the immunization card to every health visit.
- If doses were missed, return promptly. The schedule can be continued; it usually does not need restarting.
- Seek urgent care for breathing difficulty, facial swelling, persistent lethargy, seizures, persistent inconsolable crying, high fever, or signs of anaphylaxis after vaccination.
- Continue breastfeeding and normal feeding after vaccination.
- Oral polio drops should still be taken during Pulse Polio rounds even if the child has received routine OPV/IPV doses.
A recent systematic review found that interventions such as caregiver education, reminder systems, outreach, and reducing access barriers can improve routine childhood vaccine uptake in low- and middle-income countries, though the exact effect varies by setting (
BMJ Open review).